NeuShen Therapeutics, a Shanghai and Boston biotech led by a veteran transpacific drug developer, raised more than $80 million in a Series B financing to advance three clinical-stage brain-health programs. The funding supports continued development across its pipeline of central nervous system-targeted therapies. The deal signals continued investor appetite for late clinical-stage neuroscience assets with credible clinical pathways, even as funding conditions remain selective across the broader biotech market. NeuShen’s emphasis on brain-health aligns with ongoing demand for modalities that can address difficult-to-treat neurological diseases. For existing shareholders and future partners, the capital provides runway to push programs through upcoming trial milestones and potentially broaden the company’s partnering strategy for later-stage development.